Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs (NASDAQ: ESTA) has appointed Raj Denhoy as Chief Financial Officer, effective immediately. Denhoy, who joined the company in February 2021 and served as Interim CFO since August, has extensive experience in medical device research. CEO Juan José Chacón-Quirós highlighted Denhoy's understanding of the business and industry vision. Denhoy expressed optimism about the company's potential to lead in breast aesthetics and reconstruction, emphasizing innovation and stakeholder value.
Establishment Labs Holdings (NASDAQ: ESTA) announced the immediate appointment of Leslie Gillin to its Board of Directors, bringing extensive experience in consumer marketing and finance. CEO Juan José Chacón-Quirós expressed confidence in Gillin's ability to enhance patient engagement and innovative business models. Gillin, formerly of JPMorgan Chase and Citibank, aims to leverage the company’s unique technologies for improved patient experiences and expanded market presence. Established in 2010, Establishment Labs focuses on breast health with over 1.8 million Motiva Implants® sold globally.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Stephens Annual Investment Conference from December 1-3, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will speak on December 2 at 1:00 pm CT. The presentation will be available via live webcast on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women's health, providing innovative breast aesthetics solutions, including its Motiva Implants, with over 1.8 million units delivered since 2010.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in two investment conferences. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will attend the Jefferies London Healthcare Conference on November 16, 2021, and the Canaccord Genuity Virtual MedTech Forum on November 18, 2021. Live webcasts of their presentations will be available on the Establishment Labs investor relations website, with archived versions accessible afterward. The company specializes in breast aesthetics and reconstruction, offering innovative silicone gel-filled implants globally.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported third-quarter 2021 revenue of $29.0 million, up 27.6% year-over-year. Gross profit margin improved to 67.6%, while operating expenses increased to $28.7 million, driven by a return to normal business conditions. The company raised its 2021 revenue guidance to $124 million to $128 million, a growth of 46% to 51% over 2020. A net loss of $9.0 million was recorded. The company launched the Motiva Flora® tissue expander, and its Motiva implants are on track for U.S. and China market entry.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Jeffrey Bettinger as Global Head of People. Bettinger, previously Chief People and Places Officer at Nu Skin, joins the executive team with a focus on culture and human capital strategy. CEO Juan José Chacón-Quirós emphasized the importance of people and culture for the company's upcoming growth and global expansion. Measuring past success in leadership development, Bettinger aims to innovate within the Femtech industry to positively impact women's lives. Establishment Labs specializes in breast aesthetics and has delivered over 1.8 million Motiva Implants in 80+ countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q3 2021 on November 9, 2021, before market opens. Following this, a conference call is scheduled at 8:30 AM ET to discuss the results. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering products like Motiva Implants®. Since 2010, over 1.6 million implants have been distributed worldwide in over 80 countries. The company is focused on regulatory approvals for its innovative products.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) launched JOY™, a new patient-centric breast aesthetics program featuring the latest Motiva Ergonomix2® implants. JOY offers comprehensive support, including the Motiva Woman’s Choice Program™, which provides financial assistance for implant removal, and surgeon options for reverse procedures at no additional cost. Announced at the 6th World Symposium on Ergonomic Implants in Italy, JOY aims to enhance the experience for women undergoing breast surgery by combining advanced implant technology with specialized surgeon training.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its support for Breast Cancer Awareness Month in October, focusing on improving access to breast reconstruction. The company will implement the Pink is for Power program in Brazil, providing 200 women with reconstruction surgeries. Key events planned include the Motiva Breast Health Day in Barcelona and the Rosé for Reconstruction event in Italy. With the recent launch of their Motiva Flora tissue expander, Establishment Labs aims to enhance clinical outcomes for breast cancer patients.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) officially launched its Motiva Flora® tissue expander in Europe during a symposium at the London Breast Meeting on September 2, 2021. This RFID-enabled device aims to enhance post-mastectomy reconstruction, improving patient comfort through advanced biocompatibility and MRI imaging capabilities. CEO Juan José Chacón-Quirós highlighted the significance of Flora in capturing a substantial market share in breast reconstruction, projecting improved outcomes for women. Motiva Flora is not yet approved for distribution in the U.S.